Circassia Pharmaceuticals is engaged in the specialty respiratory pharmaceutical business. Co. sells its NIOX® asthma management products directly to specialists in the U.S., U.K. and Germany, and other countries via its network of partners. Co. has a collaboration in the U.S. in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®, and has the U.S. commercial rights to late-stage COPD product Duaklir®. Co.'s development pipeline includes a range of respiratory medicines. Co.'s principal asthma treatment, Fliveo®, is approved in the U.K. Co.'s pipeline also includes a number of inhaled medicines for COPD, including single and combination dose products.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.